Specialist IS Business Systems Analyst - Data & Analytics Technology
About the job
- A Master's degree and 6+ years of experience in Life Science, Biotechnology, Pharmacology, or Information Systems.
- Expertise in a scientific domain and related technology.
- Proven analytical, data-driven problem-solving skills.
- Interpersonal skills, multitasking ability, persuasion, negotiation of critical issues, attention to detail, and understanding of business complexity.
- Affinity for working in a DevOps environment and an Agile mindset.
- Ability to work effectively in a team environment and meet deadlines and schedules while being accountable.
- Experience writing user requirements and acceptance criteria in agile project management systems such as Jira.
- Experience managing product features for PI planning and developing product roadmaps and user journeys.
- Ability to test and validate that delivered user stories meet business expectations.
- Ability to communicate technical or complex subject matter in business terms.
- Ability to work under minimal supervision and effectively with global, virtual teams.
- Experience with or understanding of ETL tools and dashboard tools; Tableau is preferred.
- Good level of SQL understanding.
- Experience in DevOps, Continuous Integration, and Continuous Delivery methodology.
- Collaborate with business and technical teams to maintain efficient, consistent processes and ensure high-quality deliverables.
- Ensure delivery of team activities each sprint and completion of features each quarter.
- Work with Product Managers and customers to define scope and value for new developments.
- Collaborate with cross-functional teams to identify data product enhancement opportunities.
- Perform data analysis, troubleshoot issues, and support system implementation and maintenance.
- Break down Epics into Features and sprint-sized user stories, participate in backlog reviews with the development team, and plan sprint activities following SAFe methodology.
- Support the development team throughout sprint execution by clarifying requirements, addressing questions, and proactively removing blockers.
- Develop and execute product demonstrations for internal and external stakeholders.
- Maintain accurate documentation of business requirements, user stories, processes, and changes in Confluence.
- Document and report defects and issues found during testing, and work with development teams to resolve them.
- Maintain and ensure the quality and completeness of user stories in Jira.
- Co-design, upgrade, and implement data management capabilities with cross-functional teams.
- Elaborate product requirements as epics and user stories, and prepare supporting artifacts such as business process maps, use cases, and test plans for development teams.
- Work closely with developers, the Business Product Owner, and other business analysts to elaborate technical requirements, enabling delivery teams to estimate, plan, and commit to delivery and identify test cases and scenarios.
- Focus on Global Commercial Data & Analytics capabilities and support the ELMAC and JAPAC (OUS) regions.
- Experience with dashboard tools, preferably Tableau.
- Jira Align and Confluence experience is good to have.
About the company
Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
- Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
- Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.
What critics are saying
- Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
- MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
- Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.
What makes Amgen unique
- It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
- Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
- Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.
Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.